Single-use bioreactors market is estimated to attain a CAGR of 20.2% through 2027 owing to various advantages such as reduced cross contamination, cost-effectiveness, flexibility and increased productivity.

Asia-Pacific cell line development market revenue is expected to register a 13% CAGR during 2020 to 2026, driven by the presence of a large patient pool suffering from various chronic and infectious diseases. Growing investments in stem cell research, coupled with surge in demand for regenerative medicine, will also favor the regional industry growth.

Customized Bioreactor Enables Stem Cell Scientists' Major Advance in Regenerative Medicine, Published in Nature Medicine